“India’s coronavirus crisis is deepening, with hospitals buckling under increasing pressure from the second wave of infections. The South Asian country reported 259,170 new cases and 1,761 deaths over a 24-hour period on Tuesday, according to government data. It is the sixth straight day that India’s daily case count exceeded 200,000 while the daily death toll — still comparatively low — is inching higher. ”Sad any way you cut it. (Could belong in off topic.) Just trying to get my head around how Covid is playing into investment returns.
- Is it a good time to buy Asia, EM or global funds because Covid-19 has depressed those prices relative to the U.S.? Or - maybe a bad time if you think this trend will continue?
- Is the U.S. currently ahead of other countries in the Covid (infection rate) game because of (A) better governance? (B) more money and resources? or (C) a population more receptive to vaccines along with cultural differences?
- Are investors overestimating the economic rebound from Covid-19 and bidding up some prices recklessly? If so, which ones?
CNBC
Comments
2. Right now countries such as New Zealand, South Korea, and Taiwan who have gotten their COVID infection under control early and are doing well economically. US is playing catch-up with rapid deployment of vaccines (FEMA) and lots of resources. Delivering 200 million vaccines within 100 days is remarkable. However, there is a sizable population who do not want the vaccines and this will prevent US to reach the herd immunity this year. It is the rapid mutation of the coronavirus that is most concerning. The worst scenario would be the new variants would greatly reduce the efficacy of COVID vaccines, and render them much less effective. So far these variants are found to be more contagious but not necessary more lethal.
3. The FANNG stocks along with those that enable remote working have advanced more than the rest of the S&P 500. The market have broadened out the economically sensitive value stocks in fall 2020. Recent interview with Leann Sonder (Schwab) posted by @Derf also discussed the recent change of stock leadership and the direction moving toward “quality” stocks.
Suggest you read this link.
Try to stay save, Derf
Since COVID vaccines are approved under the Emergency Authorization Act, people who choose to take it on a volunteer basis. When the EAA expires the government can make it mandatory Just like smallpox and other vaccination for entering public schools.
In the meantime countries like India is facing vaccine shortage while facing thousand infection cases on a daily basis. Brazil is also facing the same issue and complicated by the incompetent political leadership.
There is an increasing consensus that the Chinese vaccine is almost worthless with efficacy of just 50% apparently just beating WHO requirements ( why does that not surprise me?) JNJ vaccine will be much better bet for EM despite very rare Cerebral vein thrombosis issues. But it will take months to roll out
TRUTH.
India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. India enjoys an important position in the global pharmaceuticals sector.Mar 22, 2021
India industry(s) overview
Sidenote: Modi was elected in 2014, and is a Trump like policy(s) leader. India broad equities investing peaked in Jan. 2018 and have not yet recovered those highs.
As an example, portfolio of Matthews India fund, MINDX is enclosed below.
https://fundresearch.fidelity.com/mutual-funds/composition/577130859